164 related articles for article (PubMed ID: 31473468)
1. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.
Weil C; Gelerstein S; Sharman Moser S; Chodick G; Barit Ben-David N; Shalev V; Shofaniyeh I; Kamalov R; Meytes D
Leuk Res; 2019 Oct; 85():106219. PubMed ID: 31473468
[TBL] [Abstract][Full Text] [Related]
2. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
3. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
Blimark CH; Turesson I; Genell A; Ahlberg L; Björkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist UH; Nahi H; Kristinsson SY;
Haematologica; 2018 Mar; 103(3):506-513. PubMed ID: 29217784
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
6. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017.
Langseth ØO; Myklebust TÅ; Johannesen TB; Hjertner Ø; Waage A
Br J Haematol; 2020 Nov; 191(3):418-425. PubMed ID: 32367512
[TBL] [Abstract][Full Text] [Related]
7. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
Jagannath S; Abonour R; Durie BGM; Gasparetto C; Hardin JW; Narang M; Terebelo HR; Toomey K; Wagner L; Srinivasan S; Kitali A; Yue L; Flick ED; Agarwal A; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):480-485.e3. PubMed ID: 29844008
[TBL] [Abstract][Full Text] [Related]
10. Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.
Ruotsalainen J; Lehmus L; Putkonen M; Lievonen J; Kallio A; Raittinen P; Summanen M; Kosunen M; Korhonen MJ
Ann Hematol; 2024 Apr; 103(4):1273-1284. PubMed ID: 38085293
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
12. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.
Pozzi S; Marcheselli L; Bari A; Liardo EV; Marcheselli R; Luminari S; Quaresima M; Cirilli C; Ferri P; Federico M; Sacchi S
Br J Haematol; 2013 Oct; 163(1):40-6. PubMed ID: 23889344
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Mohty M; Terpos E; Mateos MV; Cavo M; Lejniece S; Beksac M; Bekadja MA; Legiec W; Dimopoulos M; Stankovic S; Durán MS; De Stefano V; Corso A; Kochkareva Y; Laane E; Berthou C; Salwender H; Masliak Z; Pečeliūnas V; Willenbacher W; Silva J; Louw V; Nemet D; Borbényi Z; Abadi U; Pedersen RS; Černelč P; Potamianou A; Couturier C; Feys C; Thoret-Bauchet F; Boccadoro M;
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e401-e419. PubMed ID: 30030033
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
16. Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020-2025.
Kanas G; Clark O; Keeven K; Nersesyan K; Sansbury L; Hogea C
Future Oncol; 2021 Mar; 17(8):921-930. PubMed ID: 33200616
[No Abstract] [Full Text] [Related]
17. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
18. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period.
Rodríguez-Lobato LG; Pereira A; Fernández de Larrea C; Cibeira MT; Tovar N; Jiménez-Segura R; Moreno DF; Oliver-Caldés A; Rosiñol L; Bladé J
Br J Haematol; 2022 Feb; 196(3):649-659. PubMed ID: 34622447
[TBL] [Abstract][Full Text] [Related]
20. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
